

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

A01N 25/00

A1

(11) International Publication Number:

WO 99/53754

(43) International Publication Date:

28 October 1999 (28.10.99)

(21) International Application Number: PCT/US99/07957

(22) International Filing Date: 12 April 1999 (12.04.99)

(30) Priority Data:  
09/064,365 22 April 1998 (22.04.98) US

(71) Applicant: KENT STATE UNIVERSITY [US/US]; East Main and Lincoln Street, Kent, OH 44242 (US).

(72) Inventors: WOOLVERTON, Christopher, J.; 624 N. Willow Street, Kent, OH 44242 (US). MACPHEE, Martin, J.; 9971 Lake Landing Road, Gaithersburg, MD 20886 (US). DROHAN, William, N.; 8417 Oakford Drive, Springfield, VA 22156 (US).

(74) Agents: WEBER, Ray, L. et al.; Renner, Kenner, Greive, Bobak, Taylor & Weber, 1610 First National Tower, Akron, OH 44308 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.


(54) Title: SUBVERSION OF BACTERIAL RESISTANCE BY LOW SOLUBILITY ANTIBIOTICS



a



b



c



d

(57) Abstract

A site-specific antibiotic delivery system and related method comprising a fibrin sealant and an antibiotic releasably bound to the fibrin sealant, wherein the antibiotic is delivered *in situ* and wherein the dose of the antibiotic delivered to the organism is sufficient to kill substantially all antibiotic-resistant bacteria present in an infectious focus. Figure 1a is a scanning electron micrograph of a portion of a fibrin sealant magnified 170 times. Figure 1b is a scanning electron micrograph of fibrin sealant of Figure 1a having the antibiotic tetracycline free base (TET) embedded therein and magnified 5500 times. Figure 1c is scanning electron micrograph of a portion of the fibrin sealant of Figure 1a magnified 5500 times. Figure 1d is a scanning electron micrograph of fibrin sealant of Figure 1a having the antibiotic tetracycline free base (TET) embedded therein and magnified 5500 times.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## SUBVERSION OF BACTERIAL RESISTANCE BY LOW SOLUBILITY ANTIBIOTICS

### TECHNICAL FIELD

5 This invention generally relates to a site-specific antibiotic delivery system. More particularly, the present invention relates to a system that uses a carrier, such as a fibrin sealant, to deliver one or more antibiotics *in situ*. Specifically, the present invention relates to a system that can deliver a dose of antibiotics sufficiently high to overcome antibiotic-resistant bacteria.

10

### BACKGROUND OF THE INVENTION

Infection is the presence and successful multiplication of a microbe, such as a bacterium, virus, fungus or parasite, on or within a host or patient. An infection begins at a local nidus, or focal point, and typically results in local cellular injury due to toxins, competition for nutrients, intracellular replication, or a combination thereof. Once local cellular injury begins, the infected area is deemed an "infectious focus." Few antibiotics exhibit truly selective toxicity (*i.e.*, only toxic to bacterial cells) and therefore result in side effects to the patient.

15 Side effects such as allergy, renal or hepatic injury, nerve cell damage, hypotension and neutropenia are common during the systemic use of antibiotics and thus limit the dose of antibiotics that can be used to treat the infection. These side effects are often due not only to a lack of selective toxicity, but also to the systemic absorption of the drug.

20 Since the 1940s, bacterial infections have been very successfully treated with antibiotics. In recent years, however, infection by multi-drug resistant (MDR) bacteria has been a growing problem. It is clear that the natural selection of antibiotic-resistant bacteria has resulted from excessive, prolonged and indiscriminate use of antibiotics, as well as over-the-counter availability, resulting in the increasing occurrence of infection by antibiotic-resistant bacteria. Increased antibiotic prophylaxis, the use of broad-spectrum agents and the poor education of patients and prescribers regarding the need and use of antibiotics have compounded the problem. For purposes of this specification, "MDR," "resistant," and "antibiotic resistant" bacteria refer to those bacteria so classified by federal testing agencies and as understood by one of ordinary skill in the art.

While there are numerous individual mechanisms, in general, antibiotics damage bacteria via discrete interaction with structural components or metabolic pathways. The biochemical mechanisms by which bacteria resist antibiotic activity may include prevention of drug entry into the cell, rapid extrusion of the drug from the cell, enzymatic inactivation of the drug or alteration of the molecular target. Also participating in the increasing resistance are the so-called "non-canonical mechanisms" of gene dosage, heterologous induction, population resistance and low resistance synergism.

Current attempts to control infection by antibiotic-resistant bacteria include multiple-antibiotic therapies, supplementation of antibiotics with resistance inhibitors, immune modulating drugs, or combinations thereof. In many cases, systemic antibiotic concentrations exceed recommended levels, resulting in host toxicity.

Local therapy has some advantages over systemic therapy. First, as discussed, selective toxicity may not be achieved with conventional treatment. Second, systemic drug delivery may be unnecessary, unsafe or contra-indicated. Third, the maximum tolerable systemic dose of antimicrobial agent may not be efficacious due to poor vascularization, chronicity of infection or, more importantly, resistant microbes.

For purposes of this specification, "host toxicity," "whole animal toxicity," or merely "toxicity" refers to the subjective evaluation of the overall health of a patient as commonly known and understood by one of ordinary skill in the art. "Low toxicity" or "substantially non-toxic" means there are no or only minor side effects, as determined, for example, by phase I studies. By contrast, "cellular toxicity" refers to injury to cells, such as measured by a fluorescein assay.

Fibrin sealant has several unique characteristics which make it suitable as a delivery matrix for pharmaceuticals, such as antibiotics, in a patient. First, fibrin sealant is hemostatic, *i.e.*, reduces bleeding, which may facilitate healing. Second, the cross linked fibrin monomers of fibrin sealant create pores of proper size to trap and then release various pharmaceutical compounds. Third, release of trapped compounds is governed by a diffusion-dissolution mechanism, whereby the compound slowly dissolves when it is within the fibrin sealant matrix and also when it is released during the natural fibrinolysis process. For example, fibrin sealant has been used to deliver demineralized bone and bone morphogenetic proteins to repair bone defects in rats, to deliver acidic fibroblast growth factor-1 to Teflon shunts for endothelial cell recruitment forming artificial vascular grafts in dogs, to deliver antiproliferative chemotherapeutic agents in a mouse model of human

ovarian cancer and to deliver antibiotics to treat infection. Commercial laboratories manufacture fibrin sealant components primarily for homeostasis, such as the treatment of large surface area wounds in clotting-factor-deficient victims and the sealing of post-operative micro vascular leakage.

5 Antibiotic-supplemented fibrin sealant is also known. Greco et al., *J. Biomed. Materials Res.*, 25:39 (1991), for example, discloses that antibiotics were found to be almost completely released by 96 hours, the greatest percentage of material (greater than 85 percent) having been released within 72 hours. Release of antibiotics over this relatively short time period most likely resulted from the rapid diffusion of small ionic  
10 molecules designed for maximum absorption during oral and parenteral delivery of a clinical formulation. This rapid release from fibrin sealant is clinically unacceptable when a longer course of treatment is required.

It is also known that a low dose of low-solubility antibiotics can be released from fibrin sealant to kill non-resistant bacteria. "Low solubility," as used herein, refers  
15 to a species that one of ordinary skill in the art would describe as having a low solubility in water. Typically, such compounds are described in the Merck Index as "poorly soluble," "practically insoluble," "slightly soluble," "sparingly soluble," etc. Generally, such compounds have a solubility less than about 2 mg/mL at room temperature. Preferably, such compounds have a solubility less than about 1 mg/mL.

20 A need remains for a formulation and method that will deliver a high dose of antibiotic that can overcome antibiotic-resistant bacteria with low host toxicity. Heretofore, the prior art cast serious doubt on the feasibility of such a formulation. First, Greco et al. and Thompson et al., *Southern Medical J.* 90:681 (1997), teach that increasing the loading dose of antibiotic onto fibrin sealant slows coagulation by interfering with the  
25 formation of fiber from fibrinogen. Second, heretofore it was uncertain whether the host toxicity could be kept low upon the administration of an effective high dose of antibiotic.

### SUMMARY OF INVENTION

30 It is therefore an object of the present invention to provide a site-specific antibiotic delivery system.

It is another object to provide a fibrin-antibiotic delivery system such that the antibiotic releases from the fibrin in high concentrations *in vivo*.

It is yet another object of the present invention to provide a system that will deliver antibiotics in a dose sufficient to kill antibiotic-resistant bacteria.

It is another object of the present invention to provide a method for the site-specific delivery of antibiotics.

5 At least one or more of the foregoing objects, together with the advantages thereof over the known art relating to antibiotic delivery systems, which shall become apparent from the specification which follows, are accomplished by the invention as hereinafter described and claimed.

10 In general, the present invention provides a method of delivering a high dose of antibiotic comprising the step of inserting an antibiotic releasably bound to a carrier into an organism wherein the antibiotic is delivered *in situ*, wherein the dose of antibiotic delivered to the organism is sufficient to kill substantially all antibiotic-resistant bacteria present in an infectious focus.

15 The present invention also provides a site-specific antibiotic delivery system comprising a carrier and an antibiotic releasably bound to the carrier, wherein the antibiotic is delivered *in situ* and wherein the dose of antibiotic delivered to the organism is sufficient to kill substantially all antibiotic-resistant bacteria present in an infectious focus.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1a is a scanning electron micrograph of a portion of a fibrin sealant magnified 170 times.

Fig. 1b is a scanning electron micrograph of the fibrin sealant of Fig. 1a having the antibiotic tetracycline free base (TET) embedded therein and magnified 170 times.

25 Fig. 1c is a scanning electron micrograph of a portion of the fibrin sealant of Fig. 1a magnified 5500 times.

Fig. 1d is a scanning electron micrograph of a portion of the fibrin sealant of 1a having the antibiotic tetracycline free base (TET) embedded therein and magnified 5500 times.

30 Fig. 2 is a bar graph representation of the *in vitro* results of the zone of growth inhibition (mm) for six representative antibiotics at various increasing local concentrations ( $\mu\text{g/mL}$ ).

Fig. 3 is a graphical comparison of the percent of survival of test animals left untreated, or given a high dose of the antibiotic streptomycin (150 mg/kg) carried by saline or carried by a fibrin sealant implanted at a specific site within the animal to treat intra-abdominal sepsis.

5

### PREFERRED EMBODIMENT

It has now been found that direct exposure of antibiotic-resistant bacteria to an overwhelming local dose of one or more conventional antibiotics may overcome one or more mechanisms of resistance and facilitate bacterial eradication. In addition, a method  
10 has been developed to deliver a high dose of antibiotic over a period of time sufficient to kill antibiotic-resistant bacteria with low toxicity to a patient.

The present invention is efficacious and cost effective because many low solubility, synthetic antibiotic forms are cheaper precursor products which have not been used clinically. In addition, the cost of antibiotic delivery concurrent with wound  
15 debridement, culture acquisition or tissue management would be minimal compared with the cost associated with repeated surgery, a prolonged hospital stay, or an additional nosocomial infection.

Specifically, it has now been found that antibiotic-resistant bacteria can be killed using a carrier that releases a quantity of antibiotic over a long period of time  
20 sufficiently large to exceed the minimal inhibitory concentration (MIC) of the bacteria. Local delivery of an antibiotic to the focal site of infection may result in a higher therapeutic index -- the ratio of the highest non-toxic dose to the MIC required to control a microbe -- and fewer systemic side effects. Preferably, the carrier is a natural or synthetic polymer that can slowly release an antibiotic without causing harm to the patient.  
25 Accordingly, the carrier releasably binds or encapsulates an antibiotic and has pores that are big enough to allow the antibiotic to diffuse out, but small enough that the diffusion is slow. In addition, the carrier is preferably biodegradable *in vivo*, but does so sufficiently slowly to allow long-term delivery of the antibiotic. The carrier preferably has pores ranging from about 1 to about 10 microns in diameter. A highly preferred carrier is a  
30 fibrin sealant, which consists of cross-linked monomers.

As used herein, a "high dose" of antibiotic refers to the size of a single bolus in a carrier disposed in a patient such that the carrier releases the antibiotics at a rate sufficient to maintain a local concentration of antibiotic greater than or equal to the MIC

of the resistant bacteria of an infectious focus and such that the size of the bolus is sufficient to maintain the rate of delivery until substantially all of the bacteria are killed and the infectious focus is overcome.

5 Fibrin sealant is typically made of fibrinogen, thrombin and Factor XIII isolated from fractionated human plasma and treated to neutralize or remove microorganisms such as enveloped viruses. Fibrin sealant is the result of fibrin monomers that are converted from purified fibrinogen by the enzyme thrombin and cross-linked by Factor XIII. The manufacture of fibrin sealant is described by Drohan, *In Hematology: Basic Principles and Practice*, Churchill Livingston, New York (1994), p. 2019,  
10 incorporated herein by reference, and is also commercially available.

One or more antibiotics are applied to the matrix such that the antibiotic molecules become entrapped in the pores of the matrix. Use of relatively low solubility antibiotics generally increases the antibiotic effectiveness by decreasing the rapidity of release from the fibrin carrier and by increasing the local antibiotic concentration and  
15 exposure time, typically from about 1 to 3 weeks. Unlike a soluble antibiotic, a relatively insoluble one does not readily move or disperse. Furthermore, local delivery of low solubility antibiotics results in minimal systemic load and therefore minimal selective pressure on commensal microorganisms distal to the infectious focus. This is important in preventing the proliferation of resistant microorganisms and in preventing harm to  
20 beneficial microorganisms found in the body. Examples of suitable antibiotics which are poorly soluble in aqueous buffer systems include, but are not limited to, tetracycline free base (TET), streptomycin (STR), penicillin G (PEN-G), penicillin O, sulfamethoxazole-trimethoprim (SXT), norfloxacin (NOR), streptolydigin, rifamycin X, cefoxitin, and pipemidic acid. A highly preferred delivery system is biocompatible, resorbable, easy to  
25 use, inexpensive and releases efficacious amounts of drug over a predetermined time frame.

Choice of the most appropriate antibiotic is dependent upon factors such as the site of infection, the degree of antibiotic penetration into the site, the infecting bacterium, and the relative toxicity to the host. Narrow spectrum antibiotics should be used whenever  
30 possible because they exhibit the most selective toxicity toward the infecting microbe. However, the carefully standardized *in vitro* test results do not always correlate with the *in vivo* situation, where antibiotic effectiveness is altered by drug penetration and host immune response.



Fibrin sealant can be prepared with antibiotic embedded therein either in *in vitro* (and surgically implanted) or *in situ*. It is envisioned that the fibrin sealant disks will generally be implanted at the specific infection site to control local disease. The anticipated use of the present invention is primarily therapeutic, *i.e.*, after an infectious focus is discovered. But the present invention can also be used prophylactically, *i.e.*, by inserting the antibiotics into a patient before an infectious focus is discovered.

The quantity of antibiotic delivered to the patient kills substantially all antibiotic-resistant bacteria present in an infectious focus. Preferably, the quantity of loaded antibiotics is sufficiently high that the amount delivered *in situ* exceeds the saturation level of the physiological environment at the infectious focus. Accordingly, the undissolved antibiotic is less prone to leave the focus. Preferably, the concentration of the antibiotic *in situ* is maintained at a level greater than or equal to the MIC for the bacteria until substantially all of the bacteria are killed. While systemic antibiotic delivery generally requires a course of treatment of 7-10 days, it is believed that the present invention will need a shorter course of treatment, perhaps as little as 2-3 days.

Antibiotic efficacy results when the drug exhibits effective and selective toxicity on the invading bacteria. However, typical dose escalation required to control MDR infections results in significant, negative side-effects to the host. Therefore, to evaluate drug efficacy, the therapeutic index is calculated as the highest dose without host toxicity divided by the MIC. The proposed invention redefines the numerator of the fraction since relatively larger doses of less soluble antibiotic, sequestered within the carrier, are slowly released with time, posing minimal toxicity to the host. Preferably, the therapeutic index is greater than 10 and may be as high as 100 or more, but will be dependent on individual drug release kinetics.

Under typical physiological conditions (pH 7.4, 37 °C, bathed in aqueous fluid), the antibiotic molecules are released from fibrin sealant by a diffusion-dissolution mechanism. Initially, a limited number of antibiotic molecules dissolve in their aqueous environment *in vivo*. Meanwhile, the fibrin slowly breaks down by a natural fibrinolysis process, thereby increasing the surface area of the fibrin particles and exposing more antibiotic molecules to the aqueous environment. Fig. 1 shows scanning electron micrographs of fibrin sealant bound to TET (FS-TET).

*In situ* antibiotic therapy is most preferred when the antibiotic delivery kinetics can be precisely regulated, the antibiotic exerts minimal local and systemic toxicity, the

infection is suitably contained in one or few locations, and the local antibiotic concentration is significantly greater than the MIC, saturating pre-formed resistance factors and effectively inhibiting bacterial growth. It is contemplated that local antibiotic therapy would be effective in treatment concurrent with invasive procedures already required for patient management, such as surgical debridgement, culture acquisition, or exploratory investigation. Other uses include minimally invasive procedures, such as delivery via endoscopy, and in conjunction with open or chronically infected sites, such as in osteomyelitis or periodontitis.

## EXPERIMENTAL

An antibiotic was embedded in a fibrin sealant by mixing. Typically, an antibiotic is dissolved or suspended in a 133 mg/ml aqueous fibrinogen solution that contains 24 µg/ml Factor XIIIa. Prior to mixing with a solution of thrombin (330 Iu/ml) and calcium chloride (40 mmol/L), the antibiotic-fibrinogen solution is twice the desired final concentration. Alternatively, all dry materials may be admixed and hydrated at a later time period. The above materials may be mixed *in vitro* to generate the antibiotic-embedded fibrin matrix or *in vivo* through a dual-lumen syringe. The embedded fibrin sealant produced *in vitro* can then be washed with a solution such as 0.9% phosphate-buffered saline. The embedded fibrin sealant is then ready to be used *in vivo*.

Earlier studies by Woolverton et al. (unpublished) showed that prophylactic treatment of only 500 mg/kg tetracycline was required to provide 100% protection against a lethal dose of non-multi-drug resistant (NMDR) peritonitis in mice.

Local (cellular) toxicity of two forms of TET *in vitro* was evaluated using a fluorescein assay, as described by Tchao, *Progress in in vitro Toxicology*, 6:271 (1989), incorporated herein by reference. FS-TET disks of TET-HCl (20 mg/mL) or TET free base (1 mg/mL), their respective solubility limits, showed that the more soluble TET-HCl was acutely toxic, but the less soluble TET free base was nontoxic.

The duration of the prophylactic effect of FS-TET against NMDR *Staphylococcus aureus* (*S. aureus*) was maximized using a dose of 1750 mg/kg TET. This dose produced 100% survival in mice when implanted 35 days before injection of bacteria causing lethal peritonitis.

Data using a MDR isotype of *S. aureus* (ATCC 27659) demonstrate that delivery of antibiotics from fibrin sealant *in vitro* results in dose-dependent growth

inhibition (Fig. 2). The method used was that of Barry, *Am. Journal of Clinical Pathology*, 53:149 (1970), incorporated herein by reference, with modifications. Briefly, antibiotic bioactivity was assessed by agar diffusion where the agar hydrogel was seeded with bacteria prior to solidification. Several 6 mm wells were cut into the agar, the plugs were removed by aspiration and the wells were filled with the fibrin sealant hydrogel containing various concentrations of low-solubility antibiotics. Cultures were incubated for 18 h at 37 °C. Zones of growth inhibition -- the area about the well where diffused antibiotic prevents growth of seeded bacteria -- were recorded to the nearest mm and graphed in Fig. 2. The zone of inhibition required to document bacterial susceptibility to a particular concentration of antibiotic is indicated by a black horizontal bar. The data of Fig. 2 clearly demonstrate that the low solubility antibiotics were delivered from fibrin sealant as bioactive. Moreover, increasing the local concentration of low solubility antibiotics released from fibrin sealant effectively overcomes *S. aureus* resistance *in vitro*.

These data are supported *in vivo*, as well. Using the method of Weinstein et al., *Infection and Immunity*, 10:1250 (1974), incorporated herein by reference, intra-abdominal sepsis was initiated in Fisher 344 rats with the MDR *S. aureus*. Since streptomycin appeared effective *in vitro*, sepsis was initiated and followed 30 minutes later with a single *intra peritoneal* injection of 150 mg/kg streptomycin in fibrin sealant or in saline. As shown in Fig. 3, rats administered streptomycin in fibrin sealant survived sepsis initiated by MDR *S. aureus*. Rats administered streptomycin in saline did not survive, with mortality rates resembling untreated controls.

Thus it should be evident that the system and methods of the present invention are highly effective in treating bacterial infection. The invention is particularly suited for treating multi-drug resistant bacteria, but is not necessarily limited thereto. The system and method of the present invention can be used separately with other antibiotics, methods and the like.

Based upon the foregoing disclosure, it should now be apparent that the use of the delivery system described herein will carry out the objects set forth hereinabove. It is, therefore, to be understood that any variations evident fall within the scope of the claimed invention and thus, the selection of specific component elements can be determined without departing from the spirit of the invention herein disclosed and described. Thus, the scope of the invention shall include all modifications and variations that may fall within the scope of the attached claims.

## CLAIMS

What is claimed is:

- 1 1. A method for delivering to a patient a high dose of at least one antibiotic to a site  
2 containing antibiotic-resistant bacteria comprising:  
3 embedding the high dose of the at least one antibiotic in a carrier; and  
4 placing the carrier at the site,  
5 wherein the carrier releases the at least one antibiotic *in situ* at a rate and for  
6 a duration effective to kill substantially all antibiotic-resistant bacteria present in the  
7 site.
- 1 2. The method according to claim 1, wherein the antibiotic-resistant bacteria are  
2 concentrated at an infectious focus within the site.
- 1 3. The method according to claim 1, wherein at least one antibiotic has low solubility.
- 1 4. The method according to claim 1, wherein the at least one antibiotic is substantially  
2 non-toxic to the patient.
- 1 5. The method according to claim 1, wherein the carrier is a fibrin sealant.
- 1 6. The method according to claim 1, wherein the carrier releases the at least one  
2 antibiotic *in situ* in a quantity that exceeds a saturation level of at least a portion of  
3 the site.
- 1 7. The method according to claim 6, wherein the portion of the site includes an  
2 infectious focus.
- 1 8. The method according to claim 1, wherein delivery of the at least one antibiotic  
2 results in a therapeutic index greater than 10.
- 1 9. The method according to claim 1, wherein the step of placing includes inserting the  
2 carrier into an infectious focus.

- 1 10. The method according to claim 1, wherein the step of placing includes implanting  
2 the carrier into the patient.
- 1 11. The method according to claim 1, wherein the carrier releases the antibiotic over the  
2 course of at least 7 days.
- 1 12. An article suitable for delivering to a patient at least one antibiotic to a site  
2 containing antibiotic-resistant bacteria comprising:  
3 a carrier; and  
4 a high dose of the at least one antibiotic releasably carried by the carrier.
- 1 13. The article according to claim 12, wherein the carrier releases the antibiotic *in situ*  
2 at a rate and for a duration effective to kill substantially all antibiotic-resistant  
3 bacteria present in the site.
- 1 14. The article according to claim 13, wherein the carrier releases the at least one  
2 antibiotic *in situ* in a quantity that exceeds a saturation level of at least a portion of  
3 the site.
- 1 15. The article according to claim 12, wherein at least one antibiotic has low solubility.
- 1 16. The article according to claim 12, wherein the at least one antibiotic is substantially  
2 non-toxic to the patient.
- 1 17. The article according to claim 12, wherein the carrier is a fibrin sealant.
- 1 18. The article according to claim 12, wherein delivery of the at least one antibiotic  
2 results in a therapeutic index greater than 10.
- 1 19. A method for killing antibiotic-resistant bacteria present in an infectious focus of a  
2 patient comprising:

3       delivering *in situ* at least one antibiotic to the infectious focus in a dose that is  
4       substantially non-toxic to the patient and in a concentration equal to or greater than a  
5       minimum inhibitory concentration for the antibiotic-resistant bacteria; and  
6       maintaining the concentration for a period of time sufficient to kill the antibiotic-  
7       resistant bacteria.

1       20. The method according to claim 19, wherein the period of time is at least 2 days.

1       21. The method according to claim 19, wherein at least one antibiotic has low solubility.

1       22. The method according to claim 19, wherein the carrier is a fibrin sealant.

1/4




FIG.- 1a




FIG.- 1b

2/4




FIG.-1c



FIG.-1d







FIG. - 2

4/4

FIG. - 3

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/07957

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 25/00  
US CL : 424/405, 424/443, 424/444, 424/445, 424/447

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 424/405, 424/443, 424/444, 424/445, 424/447

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,997,425 A (SHIOYA et al) 05 MARCH 1991, Column 2, lines 1-9; column 3, lines 7-18 and 33-51)	1-22

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 JUNE 1999

Date of mailing of the international search report

11 AUG 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KATHRYNE E. SHELBORNE

Telephone No. (703) 308-1235